Kwan Elaine, Draper Brian, Harvey Samuel B, Endre Zoltan H, Brown Mark A
UNSW, Sydney, NSW, and; St George Hospital, Kogarah, Sydney, NSW, Australia.
UNSW, Sydney, NSW, and; Prince of Wales Hospital, Randwick, Sydney, NSW, Australia.
Australas Psychiatry. 2019 Oct;27(5):444-449. doi: 10.1177/1039856219859281. Epub 2019 Jul 9.
Depression in dialysis patients is often undetected despite associations with poor outcomes. The aim was to determine the prevalence and associations of depressive symptoms and physician recognition of depression within a typical Australian dialysis population.
A cross-sectional study examined haemodialysis and peritoneal dialysis patients of two hospitals in Sydney. Participants were screened for depression using the Hospital Anxiety and Depression Scale (HADS).
One hundred and ten patients completed the HADS. Subjects had a mean age of 63.7 years, 37% from a culturally and linguistically diverse background, and median dialysis duration of 2 years. Forty-one per cent of participants had significant depressive symptoms, of whom 42% had been diagnosed with depression by their clinicians. After adjustment for sociodemographic factors, having >10 medications prescribed, >3 hospitalisations in the last 12 months, and a history of depression were associated with depression.
Depressive symptoms are prevalent in Australian dialysis patients. Robust evidence is needed on the effectiveness of treatments for depression in changing outcomes in chronic kidney disease.
尽管透析患者的抑郁症与不良预后相关,但往往未被发现。本研究旨在确定典型澳大利亚透析人群中抑郁症状的患病率、相关性以及医生对抑郁症的识别情况。
一项横断面研究对悉尼两家医院的血液透析和腹膜透析患者进行了检查。使用医院焦虑抑郁量表(HADS)对参与者进行抑郁症筛查。
110名患者完成了HADS评估。受试者的平均年龄为63.7岁,37%来自文化和语言背景多样的群体,透析时间中位数为2年。41%的参与者有明显的抑郁症状,其中42%已被临床医生诊断为抑郁症。在对社会人口学因素进行调整后,服用超过10种药物、在过去12个月内住院超过3次以及有抑郁症病史与抑郁症相关。
抑郁症状在澳大利亚透析患者中普遍存在。需要有力证据证明抑郁症治疗对改善慢性肾病预后的有效性。